Innovation Pharmaceuticals Signs Deal to Use Tablet Technology for Oral Brilacidin Treatment

Innovation Pharmaceuticals Signs Deal to Use Tablet Technology for Oral Brilacidin Treatment
Innovation Pharmaceuticals has signed an agreement to use OralogiK — an advanced tablet-coating technology patented by BDD Pharma — to develop tablets for targeted oral delivery of Brilacidin for treating people with inflammatory bowel disease (IBD). The technology transports the medicine from the mouth, through the digestive system, to the colon, where it is needed. Brilacidin is a synthetic small molecule that structurally resembles some of the proteins the body makes to fight off bacteria and other microbial invaders. Because of this, it's being tested as an antibiotic. However, Brilacidin also has immunomodulatory properties — meaning it can decrease inflammation and even promote wound healing — that make it a potential treatment for IBD. Data from a proof-of-concept clinical trial in people with ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS) — a type of ulcerative colitis that itself is a form of IBD — demonstrated the safety and efficacy of this treatment. In that trial, Brilacidin was administered via enema. Most patients treated with Brilacidin went into clinical remission. Enemas are not generally considered the most desirable way for patients to take their medicine. However, getting a therapeutic molecule from the mouth, all the way through the digestive track, to t
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *